Tag: Oncology

Japanese drugmaker Eisai & Co and Chinese drug developer Bliss Biopharmaceutical (Hangzhou) Co., have entered into a joint development agreement to further develop BB-1701, an antibody-drug conjugate (ADC). As part of the agreement Eisai & Co obtained option rights for a strategic collaboration.

For some time now, cancer drug developers have known “Project Optimus” and new dose optimization expectations are coming their way from the Food and...

Alameda- (California-) based Exelixis confirmed that it has signed a partnership agreement with Catalent to develop multiple antibody-drug conjugates (ADCs) using Catalent's proprietary SMARTag®...

Antibody-drug conjugates or ADCs are complex immunoconjugates. They are designed to selectively deliver a small-molecules cytotoxic payload to cancer cells. Directed to specific tumor...

Antibody drug conjugates (ADCs) are a class of therapeutics that combine the selective targeting properties of monoclonal antibodies (mAbs) with potent cell killing activities of cytotoxic agents. Given rapid pace of progress in this field, it is important for drug developers to have a high level view of the landscape of ADCs in the clinic. This review analyzes ADCs tested in the field of Oncology. Trials are evaluated by cancer type, trial status, phase, and characteristics of the ADC.

New, updated, data from a phase II clinical trial of brentuximab vedotin (Adcetris®; Seattle Genetics) in patients with diffuse large B-cell lymphoma or DLBCL and other B-cell non-Hodgkin lymphomas, demonstrated an encouraging activity and tolerability profile in the relapsed and refractory setting. The results were presented at the 55th annual meeting of ASH®, the American Society of Hematology, held in New Orleans, Louisiana, USA, from December 7 - 10, 2013.

Results of a randomized phase III trial evaluating the efficacy and toxicity of sequential gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit in...

Welcome to ADC Review, Journal of Antibody-Drug Conjugates, a new online, peer-reviewed, open-access hybrid publication for those involved in the ongoing--and exciting--development of antibody-drug...

Six out of nine pediatric patients with relapsed or refractory Hodgkin lymphoma (HL) (n=5)or systemic anaplastic large cell lymphoma (sALCL) (n=4)achieved complete remission (CR)...

While 70 to 80% of all newly diagnosed patients with adult Hodgkin lymphoma are typically cured with combination chemotherapy of three or four agents...